233 results
Page 2 of 12
6-K
EX-99
o87q nvxrm3wp80esp
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
9du bszib
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
59iqjhcj0yclr xhs79m
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
8cwvzy y0tpgip3j
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-1
54a1zd
17 Jul 23
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic
7:10am
6-K
EX-99
cndkqa8i1
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
wg2kbdi86y 1julk
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
vihh35r8v
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
4ytdlntze 0ii
25 Apr 23
Current report (foreign)
7:07am
6-K
EX-99
2plo2f21hi
17 Apr 23
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating
11:08am
6-K
EX-99
a7nhv3
20 Dec 22
BioLineRx Announces Results from Phase 1/2a Study of Investigational
7:08am
6-K
EX-99
voqy1n0bc43fp zqy
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
gt1cn8 bflbui
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
0isvd0h wucrth5
10 Nov 22
Current report (foreign)
7:08am
6-K
EX-99
1rnes 2oz04
4 Nov 22
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
4:35pm
6-K
EX-99
8iz6v9233p2yjjj524
3 Nov 22
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma
9:20am
6-K
EX-99
z464wfg856mtx4b
27 Sep 22
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
7:00am
6-K
EX-10.1
kxx da8arkvn
21 Sep 22
Current report (foreign)
8:00am
424B5
489315vjp ba5
20 Sep 22
Prospectus supplement for primary offering
4:30pm
6-K
EX-99
g788x
19 Sep 22
BioLineRx Announces $15 Million Registered Direct Offering
8:08am